Hem › Sickelcellssjukdom › New York
Kliniska studier för Sickelcellssjukdom i New York
21 studier för Sickelcellssjukdom söker deltagare vid platser i New York.
Städer i New York
Officiell studietext (engelska)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Childrens Hospital at Montefiore, The Bronx
RekryterarFas 3
Ålder 12 till 100 · Alla kön · Uppdaterad 28 sep. 2026 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- Mount Sinai Hospital, New York
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT07187973A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Columbia University Medical Center_New York_0, New York
- Columbia University Medical Center_New York_0, New York
RekryterarFas 3
Ålder 2 och äldre · Alla kön · Uppdaterad 18 sep. 2026 · NCT06609226A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- NYC Health+Hospitals, Brooklyn
- Interfaith Medical Center, Brooklyn
- Cohen Children's Medical Ctr, Queens
- och 2 fler
RekryterarFas 3
Ålder 12 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT06612268A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Icahn School of Medicine at Mount Sinai, New York
- Jacobi Medical Center, The Bronx
RekryterarFas 2/3
Ålder 12 och äldre · Alla kön · Uppdaterad 18 aug. 2026 · NCT05431088ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Western New York BloodCare, Buffalo
- Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center, Hyde Park
- Weill Cornell Medical College - New York Presbyterian Hospital, New York
- och 2 fler
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 17 aug. 2026 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Mount Sinai Medical Center, New York
- Jacobi Medical Center, The Bronx
RekryterarFas 2
Ålder 12 och äldre · Alla kön · Uppdaterad 14 aug. 2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Jacobi Medical Center, The Bronx
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 5 aug. 2026 · NCT07224360The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Richmond University Medical Center- Site Number : 8400038, Staten Island
- Montefiore Medical Center - Moses Campus- Site Number : 8400057, The Bronx
RekryterarFas 3
Ålder 10 till 65 · Alla kön · Uppdaterad 29 juli 2026 · NCT06975865Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
- New York Medical College, Valhalla
RekryterarFas 2
6 Months – 21 Years · Alla kön · Uppdaterad 27 juli 2026 · NCT02675959Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering, New York
RekryterarFas 1/2
Ålder 12 till 50 · Alla kön · Uppdaterad 2 juli 2026 · NCT04819841131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
- Columbia University Irving Medical Center, New York
RekryterarFas 1
Ålder 12 till 50 · Alla kön · Uppdaterad 10 juni 2026 · NCT07015684Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Roswell Park (MRD-HCT), Buffalo
- Columbia Presbytarian (NT-DMT), New York
- Cohen's Children Hospital (NT-DMT), Queens
- och 4 fler
RekryterarObservationsstudie
Ålder 3 till 20 · Alla kön · Uppdaterad 4 juni 2026 · NCT06941389A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- Memorial Sloan Kettering Suffolk - Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre
RekryterarFas 2
Ålder 2 till 50 · Alla kön · Uppdaterad 3 juni 2026 · NCT05736419Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New York
RekryterarFas 3
Ålder 12 till 35 · Alla kön · Uppdaterad 23 mars 2026 · NCT05477563Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Columbia University, New York
RekryterarFas 2
Ålder 2 till 25 · Alla kön · Uppdaterad 10 mars 2026 · NCT03587272A Long-term Follow-up Study in Patients Who Received BEAM-101
- Columbia University Irving Medical Center, New York
RekryterarObservationsstudie
Ålder 14 till 37 · Alla kön · Uppdaterad 28 jan. 2026 · NCT07373639Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- Weil Cornell Medical College, New York
- University of Rochester Medical Center, Rochester
Rekryterar
Ålder 16 till 30 · Alla kön · Uppdaterad 7 jan. 2026 · NCT06374238Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
- Mount Sinai Hospital, New York
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2025 · NCT05519111AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
- New York Medical College, Valhalla
RekryterarFas 2
1 Day – 30 Years · Alla kön · Uppdaterad 8 aug. 2025 · NCT04099966Cannabidiol in Sickle Cell Disease
- Icahn School of Medicine at Mount Sinai, Manhattan
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 juni 2025 · NCT06930703Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.